This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cosmetic Surgery Stocks Keep Stiff Upper Lip

The restatement remarks, which attracted several lawsuits, didn't cause analysts to change their views that Medicis faces challenges in defending its turf while trying to expand its offerings. About one-third of Medicis' revenue comes from the dermal filler Restylane. While Botox works on forehead wrinkles, dermal fillers are targeted for lines around the mouth and nose.

Analysts at Credit Suisse and Roth Capital Partners recently issued reports warning that Restylane sales will be squeezed by a weaker economy and stronger competition. Allergan has a new dermal filler, Juvederm, and Mentor has a new one called Prevelle Silk. Mentor has completed clinical trials on two other dermal fillers.

Medicis also is awaiting an FDA verdict on Reloxin, a potential challenger to Botox. The FDA rejected the Reloxin application earlier this year. The application has been refiled, and analysts expect the drug to reach the market next year. Any delay "might give Allergan a lead that Medicis can never get back," Viksjo says in a recent report.

Another issue is the acne drug Solodyn, a rising star that also is subject of a patent challenge. Viksjo says the patent dispute is complex, and he believes Medicis has a good chance to protect the product until 2013. If generic competition starts as early as 2010, he would consider cutting his fair value estimate of the stock to $13 from $24.
4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRX $0.00 0.00%
AGN $216.56 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs